Webinar: Outcomes of the Paediatric ARV Drug Optimization 4 (PADO 4) and Paediatric Hepatitis C Drug Optimization meetings
19 December 2018
The WHO-led Paediatric ARV Drug Optimization 4 (PADO 4) and Paediatric Hepatitis C Drug Optimization meetings took place from 10-12 December 2018. These groups provide evidence-based priority lists with clear and consistent message to guide industry and interested stakeholders on the most needed formulations to be developed. The lists help reduce the number of unnecessary formulations being developed, and continue to be a critical tool to focus efforts and resources. The webinar covered the main outcomes of these prioritization exercises with regards to paediatric HIV and HCV drug optimization.